AEON Biopharma, Inc. (NASDAQ:AEON – Get Free Report) was down 7.6% during mid-day trading on Friday . The stock traded as low as $0.65 and last traded at $0.67. Approximately 456,838 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 798,519 shares. The stock had previously closed at $0.73.
AEON Biopharma Stock Down 7.6 %
The stock has a market capitalization of $745,040.00, a PE ratio of 3.72 and a beta of 0.26. The stock has a fifty day moving average of $6.06 and a 200-day moving average of $37.60.
Institutional Trading of AEON Biopharma
A number of large investors have recently made changes to their positions in the company. HighTower Advisors LLC purchased a new stake in shares of AEON Biopharma in the 3rd quarter valued at approximately $25,000. Caprock Group LLC acquired a new position in shares of AEON Biopharma during the third quarter worth $66,000. Geode Capital Management LLC increased its holdings in AEON Biopharma by 30.1% in the third quarter. Geode Capital Management LLC now owns 243,168 shares of the company’s stock valued at $255,000 after buying an additional 56,310 shares during the last quarter. Finally, Formidable Asset Management LLC raised its stake in AEON Biopharma by 76.8% in the fourth quarter. Formidable Asset Management LLC now owns 689,182 shares of the company’s stock valued at $372,000 after buying an additional 299,400 shares in the last quarter. 22.78% of the stock is currently owned by hedge funds and other institutional investors.
About AEON Biopharma
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.
Featured Articles
- Five stocks we like better than AEON Biopharma
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- FedEx Delivers Another Crushing Blow to Its Stock Price
- How to Buy Cheap Stocks Step by Step
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- Breakout Stocks: What They Are and How to Identify Them
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
